Post-Grant Review Of Multiple Sclerosis Treatment Patent Sought
ALEXANDRIA, Va. — A claimed method of treating multiple sclerosis (MS) with the injection of 40 milligrams of glatiramer acetate (GA) thrice weekly should not have received federal patent protection, Amneal...To view the full article, register now.
Already a subscriber? Click here to view full article